Guillain-Barré Syndrome (GBS) Clinical Trials and Treatments

Guillain-Barré syndrome is an acute autoimmune polyneuropathy in which the immune system mistakenly attacks components of the peripheral nervous system. In the most common form (acute inflammatory demyelinating polyneuropathy or AIDP), antibodies target the myelin sheath surrounding peripheral nerves, disrupting nerve signal transmission and causing rapidly progressive weakness. The condition typically begins with tingling and weakness in the feet and legs that ascends over hours to days, potentially involving the arms, trunk, cranial nerves, and respiratory muscles.

The most common symptoms of Guillain-Barré Syndrome include Tingling or weakness starting in the feet and legs, spreading upward, Difficulty walking, climbing stairs, or using facial muscles, Muscle weakness affecting both sides of the body, Chest weakness that may affect breathing, Deep muscle pain, especially in back and legs, among others. Guillain-Barré Syndrome affects approximately 1 in 60,000 people per year in the U.S. (3,000 to 6,000 new cases annually). Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Guillain-Barré Syndrome from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Clinical trials for Guillain-Barré syndrome are exploring complement inhibitors and other immunomodulatory approaches that target the specific immune pathways driving nerve damage. Annexon Biosciences' ANX005, a C1q inhibitor, has completed Phase 3 and is pursuing regulatory approval, representing a potentially more targeted treatment than current IVIG or plasma exchange.

As of September 2026, Trial Friend's curated drug index does not include an FDA-approved treatment specific to Guillain-Barré Syndrome. The Treatments section of this page checks FDA drug labels live and lists any approved drug whose label names the condition, and the trials listed below cover the investigational options.

Guillain-Barré Syndrome is an acquired condition, not an inherited one. A post-infectious immune attack on peripheral nerves; almost all cases are sporadic and no genetic test has a role. The condition affects approximately 1 in 60,000 people per year in the U.S. (3,000 to 6,000 new cases annually).

Eligibility for Guillain-Barré Syndrome clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Guillain-Barré Syndrome clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.